Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study
Copyright © 2021 Elsevier Masson SAS. All rights reserved..
PURPOSE: To evaluate the effects of metformin alone and combined treatment with metformin and an SGLT2 inhibitor on retinal microvascular morphology using optical coherence tomography angiography (OCTA) in isolated type 2 diabetes mellitus (DM) patients with HbA1c above the expected target (>7%).
METHODS: Fifty patients with isolated DM, 7%<HbA1c<8%, without diabetic retinopathy (DR) using 500mg metformin ×2 for glycemic control were included in the study. OCTA and BMI measurements were obtained at the first evaluation. Treatment was changed to metformin 1000mg ×2. Patients who did not develop side effects due to the metformin were defined as the metformin-tolerant group (group-1). Patients who developed side effects were defined as the metformin-intolerant group (group-2), and their treatment was changed to metformin 500mg ×2 and empagliflozin 10mg. The second evaluation was performed three months after the last treatment change.
RESULTS: HbA1c was lower on the second evaluation in both groups (P<0.001, in both). On the second evaluation in group-1, a decrease was found in superficial perifoveal and deep parafoveal macular vascular plexus densities (P: 0.040 and P: 0.020, respectively). No statistically significant difference was observed in group-2.
CONCLUSION: SGLT2 inhibitors may contribute to preventing the development of preclinical DR. In patients with metformin intolerance, adding SGLT2 inhibitors may be a reasonable choice to protect the retina.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Journal francais d'ophtalmologie - 44(2021), 8 vom: 15. Okt., Seite 1159-1167 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sabaner, M C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.09.2021 Date Revised 29.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfo.2021.01.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327898720 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327898720 | ||
| 003 | DE-627 | ||
| 005 | 20231225201811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jfo.2021.01.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327898720 | ||
| 035 | |a (NLM)34244004 | ||
| 035 | |a (PII)S0181-5512(21)00308-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sabaner, M C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2021 | ||
| 500 | |a Date Revised 29.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a PURPOSE: To evaluate the effects of metformin alone and combined treatment with metformin and an SGLT2 inhibitor on retinal microvascular morphology using optical coherence tomography angiography (OCTA) in isolated type 2 diabetes mellitus (DM) patients with HbA1c above the expected target (>7%) | ||
| 520 | |a METHODS: Fifty patients with isolated DM, 7%<HbA1c<8%, without diabetic retinopathy (DR) using 500mg metformin ×2 for glycemic control were included in the study. OCTA and BMI measurements were obtained at the first evaluation. Treatment was changed to metformin 1000mg ×2. Patients who did not develop side effects due to the metformin were defined as the metformin-tolerant group (group-1). Patients who developed side effects were defined as the metformin-intolerant group (group-2), and their treatment was changed to metformin 500mg ×2 and empagliflozin 10mg. The second evaluation was performed three months after the last treatment change | ||
| 520 | |a RESULTS: HbA1c was lower on the second evaluation in both groups (P<0.001, in both). On the second evaluation in group-1, a decrease was found in superficial perifoveal and deep parafoveal macular vascular plexus densities (P: 0.040 and P: 0.020, respectively). No statistically significant difference was observed in group-2 | ||
| 520 | |a CONCLUSION: SGLT2 inhibitors may contribute to preventing the development of preclinical DR. In patients with metformin intolerance, adding SGLT2 inhibitors may be a reasonable choice to protect the retina | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiographie par tomographie par cohérence optique | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Diabète sucré | |
| 650 | 4 | |a Inhibiteur de SGLT2 | |
| 650 | 4 | |a Intolérance à la metformine | |
| 650 | 4 | |a Metformin intolerance | |
| 650 | 4 | |a Optical coherence tomography angiography | |
| 650 | 4 | |a Preclinical diabetic retinopathy | |
| 650 | 4 | |a Rétinopathie diabétique préclinique | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Duman, R |e verfasserin |4 aut | |
| 700 | 1 | |a Dogan, M |e verfasserin |4 aut | |
| 700 | 1 | |a Akdogan, M |e verfasserin |4 aut | |
| 700 | 1 | |a Vurmaz, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bozkurt, E |e verfasserin |4 aut | |
| 700 | 1 | |a Beysel, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal francais d'ophtalmologie |d 1993 |g 44(2021), 8 vom: 15. Okt., Seite 1159-1167 |w (DE-627)NLM000357944 |x 1773-0597 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2021 |g number:8 |g day:15 |g month:10 |g pages:1159-1167 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfo.2021.01.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2021 |e 8 |b 15 |c 10 |h 1159-1167 | ||